Three Years of Erlotinib in Routine Practice for Non-small Cell Lung Cancer in South East Scotland

J. A. D. Ironside, J. F. English, G. R. Kerr, A. Price, F. A. Little, S. C. Erridge, M. J. Mackean

Research output: Contribution to journalArticlepeer-review

Abstract

We present a review of 111 patients who were treated over an initial 3-year period with erlotinib. The median treatment time was 68 days and 59% of patients had stopped treatment within the first 3 months. However, 20 patients were on erlotinib for more than 12 months. Performance status and smoking history were the significant prognostic factors. The overall 3-year survival in patients who had never smoked was 26%. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)550-553
Number of pages4
JournalClinical Oncology
Volume22
Issue number7
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Dive into the research topics of 'Three Years of Erlotinib in Routine Practice for Non-small Cell Lung Cancer in South East Scotland'. Together they form a unique fingerprint.

Cite this